ASCOGU25 titles are out - Raffaele Colombo
@raffcolo.bsky.social
@ascocancer.bsky.social
oncodaily.com/blog/raffael...
#ASCOGU25 #Cancer #OncoDaily #Oncology #Medicine #Health
@raffcolo.bsky.social
@ascocancer.bsky.social
oncodaily.com/blog/raffael...
#ASCOGU25 #Cancer #OncoDaily #Oncology #Medicine #Health
Raffaele Colombo: ASCOGU25 titles are out - OncoDaily
Raffaele Colombo: ASCOGU25 titles are out / ASCOGU25, cancer, OncoDaily, Oncology, Raffaele Colombo
oncodaily.com
February 1, 2025 at 5:10 PM
ASCOGU25 titles are out - Raffaele Colombo
@raffcolo.bsky.social
@ascocancer.bsky.social
oncodaily.com/blog/raffael...
#ASCOGU25 #Cancer #OncoDaily #Oncology #Medicine #Health
@raffcolo.bsky.social
@ascocancer.bsky.social
oncodaily.com/blog/raffael...
#ASCOGU25 #Cancer #OncoDaily #Oncology #Medicine #Health
On my way back home from #ascoGU25 Great discussion yesterday by @ERPlimackMD of #CheckMate 274 / #NIAGARA in the context of perioperative + adjuvant immunotherapy in #bladdercancer @oncodaily.bsky.social @oncoalert.bsky.social
February 15, 2025 at 5:23 PM
On my way back home from #ascoGU25 Great discussion yesterday by @ERPlimackMD of #CheckMate 274 / #NIAGARA in the context of perioperative + adjuvant immunotherapy in #bladdercancer @oncodaily.bsky.social @oncoalert.bsky.social
Honored to present CABOLD study design at #ASCOGU25!
A prospective cohort assessing the feasibility of cabozantinib + nivolumab in m+ ccRCC for 70+ patients :
✅ Geriatric data at baseline & follow-up
✅ Enhanced monitoring
✅ Plasma monitoring of Cabo
#ASCOGU25 #KidneyCancer #OncoGeriatrics
A prospective cohort assessing the feasibility of cabozantinib + nivolumab in m+ ccRCC for 70+ patients :
✅ Geriatric data at baseline & follow-up
✅ Enhanced monitoring
✅ Plasma monitoring of Cabo
#ASCOGU25 #KidneyCancer #OncoGeriatrics
February 15, 2025 at 11:23 PM
Honored to present CABOLD study design at #ASCOGU25!
A prospective cohort assessing the feasibility of cabozantinib + nivolumab in m+ ccRCC for 70+ patients :
✅ Geriatric data at baseline & follow-up
✅ Enhanced monitoring
✅ Plasma monitoring of Cabo
#ASCOGU25 #KidneyCancer #OncoGeriatrics
A prospective cohort assessing the feasibility of cabozantinib + nivolumab in m+ ccRCC for 70+ patients :
✅ Geriatric data at baseline & follow-up
✅ Enhanced monitoring
✅ Plasma monitoring of Cabo
#ASCOGU25 #KidneyCancer #OncoGeriatrics
🚀 Dive into #ASCOGU25 buzz!
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TVbXz1 !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TVbXz1 !
#Oncology #SocialListening #LucidQuest
ASCO_GU_ 2025_Social_Media_Report.pdf
drive.google.com/file/d/1Q1DrPio5c6P4F3VeL-5b3UCSo7DR9hXm/view
dlvr.it
September 22, 2026 at 2:58 PM
🚀 Dive into #ASCOGU25 buzz!
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TVbXz1 !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TVbXz1 !
#Oncology #SocialListening #LucidQuest
Explore the latest research at ASCO GU 2025 - Cristiane D Bergerot
@crisbergerot.bsky.social
@ascocancer.bsky.social
oncodaily.com/blog/cristia...
#ASCOGU25 #Cancer #CETTRO #CancerResearchHospital #GenitourinaryOncology #OncoDaily #Oncology #Medicine #Health
@crisbergerot.bsky.social
@ascocancer.bsky.social
oncodaily.com/blog/cristia...
#ASCOGU25 #Cancer #CETTRO #CancerResearchHospital #GenitourinaryOncology #OncoDaily #Oncology #Medicine #Health
Cristiane D Bergerot: Explore the latest research at ASCO GU 2025 - OncoDaily
Cristiane D Bergerot: Explore the latest research at ASCO GU 2025 / ASCO GU25, cancer, CETTRO Cancer Research Hospital, Cristiane D. Bergerot, Genitourinary
oncodaily.com
January 10, 2025 at 12:13 PM
Explore the latest research at ASCO GU 2025 - Cristiane D Bergerot
@crisbergerot.bsky.social
@ascocancer.bsky.social
oncodaily.com/blog/cristia...
#ASCOGU25 #Cancer #CETTRO #CancerResearchHospital #GenitourinaryOncology #OncoDaily #Oncology #Medicine #Health
@crisbergerot.bsky.social
@ascocancer.bsky.social
oncodaily.com/blog/cristia...
#ASCOGU25 #Cancer #CETTRO #CancerResearchHospital #GenitourinaryOncology #OncoDaily #Oncology #Medicine #Health
Looking forward to watching sessions virtually and following updates. But, as a Canadian, I will not be attending any meetings in the USA until this utter nonsense against our country stops. #ASCOGU25
February 13, 2025 at 2:37 PM
Looking forward to watching sessions virtually and following updates. But, as a Canadian, I will not be attending any meetings in the USA until this utter nonsense against our country stops. #ASCOGU25
What is interesting in ASCO GU25 - Amol Akhade
@suyogcancer.bsky.social
oncodaily.com/blog/amol-ak...
#ASCOGU25 #Cancer #NigeriaTrial #OncoDaily #Oncology #ProstateCancer #TALAPRO2Trial #Medicine #Health
@suyogcancer.bsky.social
oncodaily.com/blog/amol-ak...
#ASCOGU25 #Cancer #NigeriaTrial #OncoDaily #Oncology #ProstateCancer #TALAPRO2Trial #Medicine #Health
Amol Akhade: What is interesting in ASCO GU25 - OncoDaily
Amol Akhade: What is interesting in ASCO GU25 / Amol Akhade, ASCO GU25, cancer, Nigeria trial, OncoDaily, Oncology, prostate cancer, TALAPRO-2 trial
oncodaily.com
February 8, 2025 at 8:26 PM
What is interesting in ASCO GU25 - Amol Akhade
@suyogcancer.bsky.social
oncodaily.com/blog/amol-ak...
#ASCOGU25 #Cancer #NigeriaTrial #OncoDaily #Oncology #ProstateCancer #TALAPRO2Trial #Medicine #Health
@suyogcancer.bsky.social
oncodaily.com/blog/amol-ak...
#ASCOGU25 #Cancer #NigeriaTrial #OncoDaily #Oncology #ProstateCancer #TALAPRO2Trial #Medicine #Health
Updated analysis with additional FU of EV 302 EV+P in 1st line advanced #BladderCancer
✅ PFS & OS benefit in all groups
✅ Benefit in cisplatin eligible/ineligible
✅ Safety consistent with prior analysis
✅ mDOR close to 2 years #ascoGU25 @oncodaily.bsky.social
✅ PFS & OS benefit in all groups
✅ Benefit in cisplatin eligible/ineligible
✅ Safety consistent with prior analysis
✅ mDOR close to 2 years #ascoGU25 @oncodaily.bsky.social
February 15, 2025 at 5:21 PM
Updated analysis with additional FU of EV 302 EV+P in 1st line advanced #BladderCancer
✅ PFS & OS benefit in all groups
✅ Benefit in cisplatin eligible/ineligible
✅ Safety consistent with prior analysis
✅ mDOR close to 2 years #ascoGU25 @oncodaily.bsky.social
✅ PFS & OS benefit in all groups
✅ Benefit in cisplatin eligible/ineligible
✅ Safety consistent with prior analysis
✅ mDOR close to 2 years #ascoGU25 @oncodaily.bsky.social
I love Jose’s preview list for conferences.
#ASCOGU25 list below.
Thank you Jose 👍
@tapiajc.bsky.social @alison-tree.bsky.social
#ASCOGU25 list below.
Thank you Jose 👍
@tapiajc.bsky.social @alison-tree.bsky.social
Looking forward to #ASCOGU25
#Prostate: Combos w/ iPARP- and Lu- , EZH2
#Urothelial: Updates, HER-2, FGFR3, and high-risk UTUC
#Renal: Updates, UO3B, KIM-1, HIF-2 inh and MET inh
#Testicular: RPLND advanced Seminoma
#Penile: IO-chemo for advanced Ca
@rickyfrazer1.bsky.social @jmcgrane.bsky.social
#Prostate: Combos w/ iPARP- and Lu- , EZH2
#Urothelial: Updates, HER-2, FGFR3, and high-risk UTUC
#Renal: Updates, UO3B, KIM-1, HIF-2 inh and MET inh
#Testicular: RPLND advanced Seminoma
#Penile: IO-chemo for advanced Ca
@rickyfrazer1.bsky.social @jmcgrane.bsky.social
February 10, 2025 at 6:56 AM
I love Jose’s preview list for conferences.
#ASCOGU25 list below.
Thank you Jose 👍
@tapiajc.bsky.social @alison-tree.bsky.social
#ASCOGU25 list below.
Thank you Jose 👍
@tapiajc.bsky.social @alison-tree.bsky.social
🚀 Excited for #ASCOGU25! Looking forward to groundbreaking insights and game-changers once again! 🔬 Can't wait to see what’s ahead. 🎯 Stay tuned! #UroOncology #GameChanger
@axelmerseburger.bsky.social
@axelmerseburger.bsky.social
February 8, 2025 at 2:38 PM
🚀 Excited for #ASCOGU25! Looking forward to groundbreaking insights and game-changers once again! 🔬 Can't wait to see what’s ahead. 🎯 Stay tuned! #UroOncology #GameChanger
@axelmerseburger.bsky.social
@axelmerseburger.bsky.social
Heading to #ASCOGU25? Click the link below for a list of @danafarber.bsky.social presentations from the ASCO GU Symposium, the leading specialized research and education meeting for GU cancer care.
¡️https://bit.ly/4gI3DFm
Dana-Farber at #ASCOGU25
ASCO GU Symposium is the leading specialized research and education meeting for GU cancer care.
bit.ly
February 10, 2025 at 5:30 PM
Heading to #ASCOGU25? Click the link below for a list of @danafarber.bsky.social presentations from the ASCO GU Symposium, the leading specialized research and education meeting for GU cancer care.
¡️https://bit.ly/4gI3DFm
🚨 ONCOnews Update: ASCO GU 25 news Available Now! 🚨
The latest insights from ASCO GU 25 are here! Over the weekend, updates will be shared through our ONCOnews conference section.
📲 Read the latest now on ONCOnews via the ONCOassist app! https://buff.ly/4jojbAn
#ONCOnews #ASCOGU25 #ONCOassist
The latest insights from ASCO GU 25 are here! Over the weekend, updates will be shared through our ONCOnews conference section.
📲 Read the latest now on ONCOnews via the ONCOassist app! https://buff.ly/4jojbAn
#ONCOnews #ASCOGU25 #ONCOassist
February 14, 2025 at 2:54 PM
🚨 ONCOnews Update: ASCO GU 25 news Available Now! 🚨
The latest insights from ASCO GU 25 are here! Over the weekend, updates will be shared through our ONCOnews conference section.
📲 Read the latest now on ONCOnews via the ONCOassist app! https://buff.ly/4jojbAn
#ONCOnews #ASCOGU25 #ONCOassist
The latest insights from ASCO GU 25 are here! Over the weekend, updates will be shared through our ONCOnews conference section.
📲 Read the latest now on ONCOnews via the ONCOassist app! https://buff.ly/4jojbAn
#ONCOnews #ASCOGU25 #ONCOassist
Another good summary of @anzuptrials.bsky.social / Prof Louise Emmett’s #ENZA-p trial outcomes that were shared at the recent @ascocancer.bsky.social #ASCOGU25 conference and published in @thelancet.bsky.social
#prostatecancer #mHSPC #clinicaltrials
#prostatecancer #mHSPC #clinicaltrials
🎙️ @neerajagarwal.bsky.social of @huntsmancancer.bsky.social and Dr. Peter Hoskin of @official-uom.bsky.social recap key studies from #GU25 + highlight research on prostate, bladder, and kidney cancer on the latest episode of the #ASCODailyNews Podcast: dailynews.ascopubs.org/do/practice-...
March 3, 2025 at 9:08 PM
Another good summary of @anzuptrials.bsky.social / Prof Louise Emmett’s #ENZA-p trial outcomes that were shared at the recent @ascocancer.bsky.social #ASCOGU25 conference and published in @thelancet.bsky.social
#prostatecancer #mHSPC #clinicaltrials
#prostatecancer #mHSPC #clinicaltrials
🚀 Dive into #ASCOGU25 buzz!
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TV9VQq !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TV9VQq !
#Oncology #SocialListening #LucidQuest
ASCO_GU_ 2025_Social_Media_Report.pdf
dlvr.it
August 25, 2026 at 6:05 PM
🚀 Dive into #ASCOGU25 buzz!
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TV9VQq !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TV9VQq !
#Oncology #SocialListening #LucidQuest
Most men with advanced #ProstateCancer benefit from new-generation drugs targeting the androgen receptor (ARPIs), but older patients may benefit from some ARPIs more than others.
These results from the STOPCAP meta-analysis were presented at #ASCOGU25 by @dfishstats.bsky.social.
These results from the STOPCAP meta-analysis were presented at #ASCOGU25 by @dfishstats.bsky.social.
STOPCAP study finds that most men with advanced prostate cancer benefit from new-generation hormone therapy drugs | MRC Clinical Trials Unit at UCL
13 Feb 2025
buff.ly
February 13, 2025 at 6:03 PM
Most men with advanced #ProstateCancer benefit from new-generation drugs targeting the androgen receptor (ARPIs), but older patients may benefit from some ARPIs more than others.
These results from the STOPCAP meta-analysis were presented at #ASCOGU25 by @dfishstats.bsky.social.
These results from the STOPCAP meta-analysis were presented at #ASCOGU25 by @dfishstats.bsky.social.
🚀 Dive into #ASCOGU25 buzz!
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TSZ3f9 !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TSZ3f9 !
#Oncology #SocialListening #LucidQuest
ASCO_GU_ 2025_Social_Media_Report.pdf
drive.google.com/file/d/1Q1DrPio5c6P4F3VeL-5b3UCSo7DR9hXm/view
dlvr.it
May 16, 2026 at 7:58 AM
🚀 Dive into #ASCOGU25 buzz!
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TSZ3f9 !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TSZ3f9 !
#Oncology #SocialListening #LucidQuest
🚀 Dive into #ASCOGU25 buzz!
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TN5HmY !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TN5HmY !
#Oncology #SocialListening #LucidQuest
ASCO_GU_ 2025_Social_Media_Report.pdf
dlvr.it
September 15, 2025 at 6:05 PM
🚀 Dive into #ASCOGU25 buzz!
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TN5HmY !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TN5HmY !
#Oncology #SocialListening #LucidQuest
🚀 Dive into #ASCOGU25 buzz!
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TT8Xkg !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TT8Xkg !
#Oncology #SocialListening #LucidQuest
ASCO_GU_ 2025_Social_Media_Report.pdf
drive.google.com/file/d/1Q1DrPio5c6P4F3VeL-5b3UCSo7DR9hXm/view
dlvr.it
June 22, 2026 at 7:58 AM
🚀 Dive into #ASCOGU25 buzz!
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TT8Xkg !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TT8Xkg !
#Oncology #SocialListening #LucidQuest
🚀 Dive into #ASCOGU25 buzz!
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TQ7Nkk !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TQ7Nkk !
#Oncology #SocialListening #LucidQuest
ASCO_GU_ 2025_Social_Media_Report.pdf
drive.google.com/file/d/1Q1DrPio5c6P4F3VeL-5b3UCSo7DR9hXm/view
dlvr.it
January 3, 2026 at 8:58 AM
🚀 Dive into #ASCOGU25 buzz!
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TQ7Nkk !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TQ7Nkk !
#Oncology #SocialListening #LucidQuest
🚀 Dive into #ASCOGU25 buzz!
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TS5ld7 !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TS5ld7 !
#Oncology #SocialListening #LucidQuest
ASCO_GU_ 2025_Social_Media_Report.pdf
drive.google.com/file/d/1Q1DrPio5c6P4F3VeL-5b3UCSo7DR9hXm/view
dlvr.it
April 18, 2026 at 9:19 AM
🚀 Dive into #ASCOGU25 buzz!
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TS5ld7 !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TS5ld7 !
#Oncology #SocialListening #LucidQuest
🚀 Dive into #ASCOGU25 buzz!
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TTlpYD !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TTlpYD !
#Oncology #SocialListening #LucidQuest
ASCO_GU_ 2025_Social_Media_Report.pdf
drive.google.com/file/d/1Q1DrPio5c6P4F3VeL-5b3UCSo7DR9hXm/view
dlvr.it
July 29, 2026 at 7:58 AM
🚀 Dive into #ASCOGU25 buzz!
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TTlpYD !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TTlpYD !
#Oncology #SocialListening #LucidQuest
🚀 Dive into #ASCOGU25 buzz!
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TRGBBY !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TRGBBY !
#Oncology #SocialListening #LucidQuest
ASCO_GU_ 2025_Social_Media_Report.pdf
drive.google.com/file/d/1Q1DrPio5c6P4F3VeL-5b3UCSo7DR9hXm/view
dlvr.it
March 3, 2026 at 8:59 AM
🚀 Dive into #ASCOGU25 buzz!
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TRGBBY !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TRGBBY !
#Oncology #SocialListening #LucidQuest
Puerto Rico was incredible, snuck a quick trip to San Francisco for a #ASCOGU25 meeting & back to NOLA next wk for #MardiGras. I always think it’s funny that the pic on the left is the reality of my life just as much as the pic on the right. I’ve lived many different versions of myself this month.
February 16, 2025 at 1:15 AM
Puerto Rico was incredible, snuck a quick trip to San Francisco for a #ASCOGU25 meeting & back to NOLA next wk for #MardiGras. I always think it’s funny that the pic on the left is the reality of my life just as much as the pic on the right. I’ve lived many different versions of myself this month.